Neurologic symptoms were classified into 4 categories: mononeuritis multiplex, PTS, meningoradiculitis, and acute inflammatory demyelinating polyradiculoneuropathy (Table 3).
Mononeuritis multiplex was defined by asymmetric, asynchronous involvement of the noncontiguous nerve trunks.
(60% of cases) and cutaneous vasculitis (> 60% cases) have also been reported.
Single cases of mononeuritis multiplex
[TM] and 'pseudomyasthenia' during an acute attack have been described.
The disease is also associated with general symptoms, arthritis, artralgia, mononeuritis multiplex and other manifestations (3).
According to the revised Japanese criteria for the diagnosis of MPA put forward by the National Study Group of Angiitis, the diagnosis of 'definite MPA' is made in the existence of one of the two following conditions: MPO-ANCA is detected in patients presenting with both rapidly progressive glomerulonephritis (RPGN) and pulmonary hemorrhage or histological evidence is demonstrated in patients presenting with more than any two of the following three symptoms: (I) RPGN, (II) pulmonary hemorrhage and (III) other symptoms, such as purpura, subcutaneous hemorrhage, gastrointestinal bleeding and mononeuritis multiplex (1,11,12).
With the widespread use of TNF-[alpha] inhibitors, neurological events of demyelinating disease, mononeuritis multiplex, and foot drop have been reported in conjunction with their use (2-4).
Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
If the above is normal, then an "electromyography" test may help diagnose the problem, whether it is chronic inflammatory demyelinating polyneuropathy (CIDP), Guillain-Barre-like syndrome (sometimes associated with the use of d drugs), and/or mononeuritis multiplex (see the following question).
A: Mononeuritis multiplex (MM) is uncommon and often difficult to diagnose.
The 1990 American College of Rheumatology classification criteria for CSS are as follows: 1) asthma; 2) eosinophilia of more than 10%; 3) mononeuropathy, including mononeuritis multiplex
or polyneuropathy; 4) paranasal sinus abnormality; 5) nonfixed pulmonary infiltrates; and 6) extravascular eosinophils evidenced on biopsy.
(MNM) is used to group multiple disorders with varying mechanisms of injury that cause damage to two or more separate peripheral nerves.